Development of vaccine against coronavirus 2019-nCoV

Bravo Healthcare has put together and international consortium for development and production of vaccine against coronavirus 2019-nCoV. The consortium includes partners for preclinical development and validation, clinical trials, regulatory issues, production and distribution from the USA, India, Estonia , the Netherlands and Taiwan. All consortium partners are top-level experts in their area and are able and willing to work quickly and effectively for the common goal of making efficient coronavirus vaccine widely available. The consortium is ready to give the production licence to third parties according to request.

The Bravo consortium fully understands the challenge and the very tight time-line for developing and producing the vaccine against coronavirus. We also understand the necessity to keep the production costs of the vaccine as low as possible in order to make the vaccine widely available and stop the coronavirus epidemic. Therefore use a traditional and proven approach made more effective by our team. The method is fast, safe and cost-effective and easily scalable. Ideally we would be able develop the vaccine in 10 days, finish clinical trials in 1 month and the vaccine can be ready for end-users in max 2 months.

On Feb 14, 2020 the consortium presented an application for CEPI (the Coalition for Epidemic Preparedness Innovations).